These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 15346660

  • 1. Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women.
    Christodoulakos GE, Lambrinoudaki IV, Panoulis CP, Papadias CA, Kouskouni EE, Creatsas GC.
    Gynecol Endocrinol; 2004 May; 18(5):244-57. PubMed ID: 15346660
    [Abstract] [Full Text] [Related]

  • 2. Serum lipids and apolipoproteins in Greek postmenopausal women: association with estrogen, estrogen-progestin, tibolone and raloxifene therapy.
    Creatsas G, Christodoulakos G, Lambrinoudaki I, Panoulis C, Chondros C, Patramanis P.
    J Endocrinol Invest; 2003 Jun; 26(6):545-51. PubMed ID: 12952369
    [Abstract] [Full Text] [Related]

  • 3. The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women.
    Bayrak A, Aldemir DA, Bayrak T, Corakçi A, Dursun P.
    Arch Gynecol Obstet; 2006 Aug; 274(5):289-96. PubMed ID: 16810536
    [Abstract] [Full Text] [Related]

  • 4. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.
    Godsland IF.
    Fertil Steril; 2001 May; 75(5):898-915. PubMed ID: 11334901
    [Abstract] [Full Text] [Related]

  • 5. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
    Christodoulakos G, Lambrinoudaki I, Panoulis C, Sioulas V, Rizos D, Caramalis G, Botsis D, Creatsas G.
    Maturitas; 2005 Apr 11; 50(4):321-30. PubMed ID: 15780533
    [Abstract] [Full Text] [Related]

  • 6. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.
    Kim CJ, Min YK, Ryu WS, Kwak JW, Ryoo UH.
    Arch Intern Med; 2005 Apr 11; 156(15):1693-700. PubMed ID: 8694668
    [Abstract] [Full Text] [Related]

  • 7. Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women.
    Christodoulakos GE, Lambrinoudaki IV, Creatsa MG, Economou EV, Siasou Z, Panoulis CP, Kalligerou I, Papadias C.
    Climacteric; 2008 Apr 11; 11(2):155-65. PubMed ID: 18365858
    [Abstract] [Full Text] [Related]

  • 8. Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, high-density lipoprotein subfractions and apolipoproteins in postmenopausal women in a two-year, randomized, double-blind, placebo-controlled trial.
    Kotecha PT, Godsland IF, Crook D, Stevenson JC.
    Clin Endocrinol (Oxf); 2020 Apr 11; 92(4):303-311. PubMed ID: 31925799
    [Abstract] [Full Text] [Related]

  • 9. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women.
    Anderson PW, Cox DA, Sashegyi A, Paul S, Silfen SL, Walsh BW.
    Maturitas; 2001 Jul 25; 39(1):71-7. PubMed ID: 11451623
    [Abstract] [Full Text] [Related]

  • 10. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
    Baracat EC, Barbosa IC, Giordano MG, Haidar MA, Marinho RM, Menegocci JC, Morais KM, Tomaz G, Wehba S.
    Climacteric; 2002 Mar 25; 5(1):60-9. PubMed ID: 11974560
    [Abstract] [Full Text] [Related]

  • 11. Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma.
    Christodoulakos GE, Lambrinoudaki IV, Economou EV, Papadias C, Panoulis CP, Kouskouni EE, Vlachou SA, Creatsas GC.
    J Cardiovasc Pharmacol; 2006 Apr 25; 47(4):542-8. PubMed ID: 16680067
    [Abstract] [Full Text] [Related]

  • 12. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women.
    Tilly-Kiesi M, Kahri J, Pyörälä T, Puolakka J, Luotola H, Lappi M, Lahdenperä S, Taskinen MR.
    Atherosclerosis; 1997 Mar 21; 129(2):249-59. PubMed ID: 9105568
    [Abstract] [Full Text] [Related]

  • 13. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC, Christodoulakos GE, Lambrinoudaki IV, Dalamanga A, Alexandrou AP, Bramis J, Bastounis E, Creatsas GC.
    Climacteric; 2007 Oct 21; 10(5):400-7. PubMed ID: 17852143
    [Abstract] [Full Text] [Related]

  • 14. Flow resistance in carotid and middle cerebral arteries in postmenopausal women: a comparative study of tibolone and continuous combined hormone replacement therapy.
    Pan HA, Wang ST, Chen CH, Pai MC, Wu MH, Huang KE.
    Climacteric; 2002 Sep 21; 5(3):259-65. PubMed ID: 12419084
    [Abstract] [Full Text] [Related]

  • 15. Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B.
    Castelo-Branco C, Casals E, Figueras F, Sanjuan A, Vicente JJ, Balasch J, Vanrell JA.
    Menopause; 1999 Sep 21; 6(2):92-7. PubMed ID: 10374214
    [Abstract] [Full Text] [Related]

  • 16. Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial.
    Vigna GB, Donegà P, Zanca R, Barban A, Passaro A, Pansini F, Bonaccorsi G, Mollica G, Fellin R.
    Metabolism; 2002 Nov 21; 51(11):1463-70. PubMed ID: 12404199
    [Abstract] [Full Text] [Related]

  • 17. Serum cholesterol efflux potential in postmenopausal monkeys treated with tibolone or conjugated estrogens.
    Mikkola TS, Anthony MS, Clarkson TB, St Clair RW.
    Metabolism; 2002 Apr 21; 51(4):523-30. PubMed ID: 11912565
    [Abstract] [Full Text] [Related]

  • 18. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women.
    Castelo-Branco C, Vicente JJ, Figueras F, Sanjuan A, Martínez de Osaba MJ, Casals E, Pons F, Balasch J, Vanrell JA.
    Maturitas; 2000 Feb 15; 34(2):161-8. PubMed ID: 10714911
    [Abstract] [Full Text] [Related]

  • 19. A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin.
    Milner MH, Sinnott MM, Cooke TM, Kelly A, McGill T, Harrison RF.
    Obstet Gynecol; 1996 Apr 15; 87(4):593-9. PubMed ID: 8602314
    [Abstract] [Full Text] [Related]

  • 20. The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a).
    de Kraker AT, Kenemans P, Smolders RG, Kroeks MV, van der Mooren MJ.
    Maturitas; 2004 Nov 15; 49(3):253-63. PubMed ID: 15488354
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.